Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition ...

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

Merck & Co reported stronger-than-expected quarterly earnings thanks to rising Keytruda sales. However, Gardasil's weak ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

Merck & Co posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster cancer treatment ...

Shares in Merck & Co were more than 2% lower as New York trading entered its latter half on Thursday. The US pharma giant ...